Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

es of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x10(10) TCID(50). Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical benefit rate (PR + CR + stable disease) of 74%. The Company is currently conducting a confirmatory Phase 2 trial in the U.S. in patients with advanced head and n
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... USC have developed a new microscopy technology that ... animals at higher-than-ever resolution. , Dubbed "Complementation Activated ... resolutions that are an order of magnitude finer ... the behavior of biomolecules at the nanometer scale. ... by Nature Communications , the researchers behind ...
(Date:9/18/2014)... City, MX (PRWEB) September 18, 2014 ... in Mexico City, MX. ASEA is the manufacturer of ... and the skin care product, RENU28. , The ... Regional Vice President Duvan Botero, and ASEA Field Leader ... Samuelson holds a PhD in Atomic/Medical Physics from the ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2
... Aug. 18 Sigma-Aldrich® Corporation (Nasdaq: SIAL ... been named Vice President and Chief Information Officer, effective ... lead the Company,s global information systems function and will ... Officer and Chief Administrative Officer. Borg (age ...
... 18 NephRx Corporation today announced that the U.S. ... designation to its lead product NX001 for the prevention ...  NX001 is a kidney growth factor peptide that has ... models of acute renal failure.   "Delayed ...
... FutureFuel Corp. (OTC Bulletin Board: FTFL ) filed ... special cash dividend of $0.20 per share. The ... a special cash dividend of U.S. $0.20 per share on ... 2010. The dividend is payable September 30, 2010. ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 2NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function 2
(Date:9/18/2014)... the first smartphone app that automatically reveals students, ... other words, your smartphone knows your state of ... how that affects you. , The StudentLife app, ... to their academic performance, also may be used ... monitor mental health, trigger intervention and improve productivity ...
(Date:9/18/2014)... celebrated tonight at the third annual Golden Goose Award ... premature infants and in paving the way for the ... supported by the National Science Foundation, the National Institutes ... be honored at a ceremony at the Library of ... of Congress will be on hand to help present ...
(Date:9/18/2014)... when people are too stressed they are often grouchy, ... Mind Institute (BMI) at EPFL have just highlighted a ... stress and the loss of social skills and cognitive ... synaptic regulatory molecule in the brain. This was revealed ... , Carmen Sandi,s team went to look for ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 43rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2How stress tears us apart 2
... April 27 Negotiations broke off early Tuesday morning between Temple ... (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, but ... , Temple ...
... Holdings, Inc. (NYSE: MDC ) today announced that its board of directors has ... share on the Company,s common stock.  The dividend will be paid on Wednesday, May ... , , ... , , ...
... , April 26 /PRNewswire-Asia/ -- Winner Medical ... "Company"), a leading manufacturer of,medical dressings, medical disposables and ... announced today that it has,priced a public offering of ... of, $6.10 per share. Winner Medical expects to ...
Cached Biology News:M.D.C. Holdings Declares Quarterly Cash Dividend 2Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 2Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 3Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 4
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: